News
08-16-2013, 10:40 PM
Aileron Therapeutics, Inc., a clinical stage biopharmaceutical company that is developing first-in-class therapeutics based on its proprietary Stapled Peptide drug platform, announced today the publication of preclinical data on ATSP-7041, a potent and selective stapled peptide re-activator of the wild type p53 tumor suppressor protein.
More... (http://www.news-medical.net/news/20130817/ATSP-7041-cell-penetrating-stapled-peptide-activates-p53-suppresses-tumor-growth-in-animal-models.aspx)
More... (http://www.news-medical.net/news/20130817/ATSP-7041-cell-penetrating-stapled-peptide-activates-p53-suppresses-tumor-growth-in-animal-models.aspx)